Preparation method of recombinant bombyx mori nuclear polyhedrosis virus, and preparation system and preparation method of recombinant adeno-associated virus

By infecting BMN cells with a single recombinant silkworm nucleopolyhedrovirus in low serum suspension culture or suspension-adherent culture, the problem of low rAAV yield and infection efficiency in the silkworm baculovirus system was solved, and efficient and low-cost rAAV vector preparation was achieved.

CN118909966APending Publication Date: 2024-11-08JISHIDA (SHENZHEN) BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410615864.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-05-17
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In existing technologies, the yield, full/empty capsid ratio, and infection efficiency of recombinant adeno-associated virus (rAAV) produced based on the silkworm baculovirus expression system are unsatisfactory, failing to meet the production needs of gene therapy drugs, and traditional methods are time-consuming and labor-intensive.

Method used

By infecting BMN cells in low-serum suspension culture or suspension-adherent culture with a single recombinant silkworm nucleopolyhedrovirus, P1 generation rBmBEV-rAAV was rescued and further infected with low-serum suspension cultured BMN cells to obtain progeny rBmBEV-rAAV. This simplified the plaque screening and purification process and improved the production efficiency of the rAAV vector.

Benefits of technology

This technology enables efficient, low-cost, and large-scale production of rAAV vectors with high titers, low empty shell ratios, and good infectivity, simplifying the preparation process and reducing production costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909966A_ABST
    Figure CN118909966A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method of a recombinant bombyx mori nuclear polyhedrosis virus, and a preparation system and a preparation method of a recombinant adeno-associated virus. The recombinant adeno-associated virus preparation system comprises a) low-serum suspension culture BMN cells and / or adherent culture cells of the low-serum suspension culture BMN cells, and b) recombinant bombyx mori nuclear polyhedrosis viruses, and the recombinant bombyx mori nuclear polyhedrosis viruses infect host cells or hosts at least can generate functional proteins required by packaging of the recombinant adeno-associated viruses. According to the preparation method of the recombinant adeno-associated virus provided by the invention, the BMN cells subjected to suspension culture or suspension-to-adherent culture are infected by using the recombinant bombyx mori nuclear polyhedrosis virus. The recombinant adeno-associated virus prepared on the basis of the silkworm baculovirus expression system is high in titer, low in vacant shell rate and good in infection activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and specifically relates to a preparation method of a recombinant Bombyx mori Nuclear Polyhedrosis Virus (rBmNPV), and a recombinant adeno-associated virus (rAAV) preparation system and preparation method. Background Art

[0002] Gene therapy (GT) is a new type of therapy that treats diseases through transcription and / or translation of transduced therapeutic genetic materials, such as genes, gene fragments, RNA, gene scissors, etc. Indications include genetic diseases, tumors, and chronic diseases. Currently, programs based on viral delivery of therapeutic genetic materials account for nearly 90% of the total number of gene therapies, and thousands of clinical trials based on rAAV account for more than 40% of gene therapies. To date, a number of rAAV viral vector gene therapy products have been approved for marketing, but the production costs of these products are relatively high.

[0003] Compared with the HEK293T cell / three-plasmid transfection production system, the baculovirus-based rAAV production system has the advantages of scalability, low cost and predictable biosafety, and is more suitable for the production of gene therapy drugs. At present, the insect cell / baculovirus rAAV production system is mainly based on the commercial Bac-to-Bac Autographa californica baculovirus (AcMNPV) expression system or its improved version, including the three-baculovirus system, the two-baculovirus system, the one-baculovirus system that depends on the packaging cell line, and the one-baculovirus system based on the shuttle vector (OneBac system) that does not depend on the packaging cell line. Although the OneBac system developed by the invention patents with the previous authorization publication number of CN 109609552 B, "Method, system and recombinant bacmid for preparing recombinant adeno-associated virus" and the invention patent with the authorization publication number of CN 112553257 B, "Method, system and recombinant bacmid for preparing recombinant adeno-associated virus", solved the industrial bottleneck problems of low yield, poor stability and high cost of rAAV preparation in the traditional insect cell (Sf9) / baculovirus system, the process of large-scale suspension culture of Sf9 cells using bioreactors is still expensive. Silkworm (Bombyx mori), as an important economic insect with Chinese characteristics, is easy to raise and low in cost. The live pupae in the cocoon can be used as bioreactors to produce rAAV. In particular, the development of artificial feed has laid the foundation for the large-scale, standardized and industrialized breeding of silkworms, making it possible to produce rAAV gene therapy preparations at extremely low cost using SPF-grade silkworm pupae as raw materials.

[0004] However, if the extremely low-cost silkworm pupae are used as raw materials for the preparation of rAAV gene therapy preparations, the key is to first produce rAAV with infectious activity at the cellular level based on the silkworm baculovirus expression system (BmNPV). The BmNPV expression system is another baculovirus system similar to the Autographa californica baculovirus (AcMNPV) expression system. Currently, hundreds of recombinant proteins have been expressed based on this system, including mouse interleukin 3 (IL-3), foot and foot disease subunit vaccine, human granulocyte macrophage colony stimulating factor (HGM-CSF), hepatitis B surface antigen (HBsAG) vaccine, etc., but the production of rAAV vectors is relatively lagging behind. At present, three silkworm baculoviruses (Lu Nian et al., 2018, Advances in Biotechnology, Vol. 8 (Issue 1)) and two silkworm baculovirus systems can produce rAAV2 or its chimeric virus (Qian et al., 2021, Viruses, 2021.13.704.), but the yield, full / empty capsid ratio and infection efficiency of rAAV vectors are not satisfactory and cannot meet the production needs of gene therapy drugs. The invention patent "Recombinant adeno-associated virus, its mutants and their construction methods and applications" with publication number CN 112961219A successfully prepared rAAV with infectious activity using the silkworm baculovirus expression system, but the single recombinant silkworm nuclear polyhedrosis virus (rBmNPV) involved was obtained by recombination in silkworm cells, and it was necessary to perform time-consuming and labor-intensive plaque screening to purify rBmNPV, and the rAAV prepared by this method also had the above-mentioned problems in yield, full / empty capsid ratio, infection efficiency, etc. Summary of the invention

[0005] In view of the above defects of the prior art, the present invention provides a method for preparing a recombinant silkworm nuclear polyhedrosis virus, a recombinant adeno-associated virus preparation system and a preparation method.

[0006] The specific technical solutions of the present invention are as follows:

[0007] In one aspect, the present invention provides a method for preparing a single recombinant Bombyx mori nuclear polyhedrosis virus, wherein the preparation method is selected from one of methods 1 to 3:

[0008] Method 1: Transfect the adherent cultured BMN cells cultured in low serum suspension culture with a single BmNPV-rAAV recombinant bacmid to rescue the first generation (P1) budding recombinant Bombyx mori nuclear polyhedrosis virus (rBmNPV (Budded virus)-rAAV, rBmBEV-rAAV), which is a single recombinant Bombyx mori nuclear polyhedrosis virus;

[0009] Method 2: Transfect the adherent cultured cells of low-serum suspension cultured BMN cells with a single BmNPV-rAAV recombinant bacmid to rescue the P1 generation rBmBEV-rAAV; Infect the adherent cultured cells of low-serum suspension cultured BMN cells with the P1 generation rBmBEV-rAAV to obtain the progeny rBmBEV-rAAV, which is a single recombinant Bombyx mori nuclear polyhedrosis virus;

[0010] Method 3: Transfect the adherent cultured cells of low-serum suspension cultured BMN cells with a single BmNPV-rAAV recombinant bacmid to rescue the P1 generation rBmBEV-rAAV; Infect the low-serum suspension cultured BMN cells with the P1 generation rBmBEV-rAAV to obtain the progeny rBmBEV-rAAV, which is a single recombinant Bombyx mori nuclear polyhedrosis virus;

[0011] The single BmNPV-rAAV recombinant bacmid comprises a recombinant adeno-associated virus core expression element ITR-GOI, a Rep gene expression cassette and a Cap gene expression cassette.

[0012] Furthermore, the low-serum suspension cultured BMN cells are BMN cells suspended and cultured in a culture medium containing 2% fetal bovine serum by volume;

[0013] And / or, the adherent cultured cells of the low-serum suspension cultured BMN cells are low-serum suspension cultured BMN cells adherently grown in Grace supplemented insect medium containing 10% by volume fetal bovine serum.

[0014] Furthermore, the preparation of the low-serum suspension cultured BMN cells comprises: the BMN cells are first domesticated to grow adherently in a Grace-supplemented insect medium containing 10% by volume of fetal bovine serum, then are adherently domesticated to a mixed medium consisting of an insect cell serum-free medium with a gradually decreasing fetal bovine serum content and a Grace-supplemented insect medium, and then are suspended and domesticated to a mixed medium consisting of an insect cell serum-free medium with a gradually decreasing fetal bovine serum content and a Grace-supplemented insect medium, and finally the BMN cells are stabilized in a mixed medium consisting of an insect cell serum-free medium with a volume percentage of 2% fetal bovine serum and a Grace-supplemented insect medium, and the obtained cells are low-serum suspension cultured BMN cells;

[0015] Preferably, HyPep 1510 is additionally added to the mixed medium consisting of the insect cell serum-free medium and Grace supplemented insect medium;

[0016] Preferably, the volume percentage of HyPep 1510 is 0.5%;

[0017] Preferably, the threshold value of the volume percentage of fetal bovine serum for BMN cell adherence and suspension acclimation is 5%, that is, when the volume percentage of fetal bovine serum in the mixed culture medium is lower than 5%, the BMN cells cultured adherently are switched to suspension culture;

[0018] Preferably, the volume percentage of the fetal bovine serum decreases step by step in a gradient of 10%, 7.5%, 5%, 3%, and 2%.

[0019] Furthermore, the preparation of adherent cultured cells of the low-serum suspension cultured BMN cells includes: adding the low-serum suspension cultured BMN cells to Grace supplemented insect culture medium containing 10% by volume of fetal bovine serum for adherent culture, to prepare BMN adherent cells that are in logarithmic growth phase, 75% to 85% fused and evenly distributed, and in good condition, namely, adherent cultured cells of the low-serum suspension cultured BMN cells.

[0020] Furthermore, the promoter driving the expression of the recombinant adeno-associated virus Cap gene and Rep gene is derived from AcMNPV;

[0021] Preferably, the promoter driving the expression of the Cap gene is Pp10;

[0022] Preferably, the promoter driving the expression of the Rep gene is Pph;

[0023] Preferably, the recombinant adeno-associated virus core expression element ITR-GOI and the Cap gene expression frame are located at least in the same non-essential locus of the Bombyx mori nuclear polyhedrosis virus genome.

[0024] Furthermore, the single BmNPV-rAAV recombinant bacmid is prepared with reference to the patent “A recombinant bacmid preparation system and BmNPV-rAAV recombinant bacmid, patent application number: 202311779100.4”.

[0025] The present invention also provides a single recombinant silkworm nuclear polyhedrosis virus prepared by the above preparation method.

[0026] The present invention also provides a recombinant adeno-associated virus preparation system, which comprises: a) the low-serum suspension cultured BMN cells and / or the adherent cultured cells of the low-serum suspension cultured BMN cells, and b) a recombinant Bombyx mori nuclear polyhedrosis virus, wherein the recombinant Bombyx mori nuclear polyhedrosis virus infects a host cell or a host to at least produce a functional protein required for packaging the recombinant adeno-associated virus.

[0027] Furthermore, the recombinant Bombyx mori nuclear polyhedrosis virus is a single recombinant Bombyx mori nuclear polyhedrosis virus prepared by the preparation method.

[0028] The present invention also provides a method for preparing a recombinant adeno-associated virus, which uses the recombinant adeno-associated virus preparation system to prepare the recombinant adeno-associated virus. The preparation method comprises the following steps: infecting the low-serum suspension cultured BMN cells with the recombinant silkworm nuclear polyhedrosis virus, or infecting the adherent cultured cells of the low-serum suspension cultured BMN cells with the recombinant silkworm nuclear polyhedrosis virus, and after the infection is completed, respectively collecting the culture supernatant liquid and the cell precipitate, lysing the cell precipitate, and separating and purifying to obtain the recombinant adeno-associated virus.

[0029] Further, the cell precipitate is purified by iodixanol density gradient centrifugation;

[0030] Preferably, the MOI of the recombinant Bombyx mori nuclear polyhedrosis virus is 3 to 5;

[0031] Preferably, the infection time is 72 hours.

[0032] Furthermore, the method for preparing the recombinant adeno-associated virus specifically comprises the following steps:

[0033] 1) BMN cells introduced from the American Type Culture Collection (ATCC) were first cultured in Grace's supplemented insect medium with a volume percentage of 10% fetal bovine serum, then adhered to a mixed medium with an additional HyPep1510 consisting of 7.5% fetal bovine serum, 5% insect cell serum-free medium and Grace's supplemented insect medium, and then suspended and cultured in a mixed medium with an additional HyPep1510 consisting of 3% fetal bovine serum, 2% insect cell serum-free medium and Grace's supplemented insect medium, to obtain low-serum suspension cultured BMN cells;

[0034] 2) The low-serum suspension BMN cells were transferred to the Grace-supplemented insect medium with a volume percentage of 10% fetal bovine serum for adherent culture, and the adherent cultured cells of the low-serum suspension cultured BMN cells in the logarithmic growth phase, 75% to 85% confluence, uniform adherent distribution, and good condition were prepared;

[0035] 3) transfecting the adherent cultured cells of low-serum suspension cultured BMN cells with a single BmNPV recombinant bacmid containing the functional protein expression cassette and ITR-GOI core expression element required for producing recombinant adeno-associated virus to rescue the P1 generation rBmBEV-rAAV, and the prepared P1 generation rBmBEV-rAAV infects the BMN cells cultured in low-serum suspension, or infects the BMN cells cultured in adherent culture in step 2) and is further amplified to obtain progeny rBmBEV-rAAV;

[0036] 4) The P1 generation rBmBEV-rAAV or the progeny rBmBEV-rAAV is used to infect low-serum suspension cultured BMN cells or adherent cultured cells of low-serum suspension cultured BMN cells. After 72 hours, the culture supernatant (the cell supernatant is the progeny rBmBEV-rAAV, which can be used to further infect host cells or prepare rAAV in the host) and the cell precipitate are collected respectively, and the cell precipitate is lysed and separated and purified to obtain the rAAV vector.

[0037] Compared with the prior art, the present invention has the following beneficial effects:

[0038] (1) The recombinant adeno-associated virus preparation system and preparation method provided by the present invention utilize a single recombinant Bombyx mori nuclear polyhedrosis virus to infect BMN cells that are cultured in suspension or transferred to a suspension adherent culture, thereby achieving efficient production of rAAV vectors with high titer, low empty shell rate, and good infection activity based on the Bombyx mori baculovirus expression system.

[0039] (2) The present invention provides a single recombinant Bombyx mori nuclear polyhedrosis virus and a preparation method thereof. By transfecting adherent BMN cells with a single BmNPV-rAAV recombinant bacmid, P1 generation rBmBEV-rAAV containing the recombinant adeno-associated virus core expression element ITR-GOI and the functional protein expression frame required for producing the recombinant adeno-associated virus in its genome can be rescued. The P1 generation rBmBEV-rAAV can be further infected with suspension cultured or suspension-transferred adherent BMN cells to obtain a larger number of progeny rBmBEV-rAAVs. This method of purifying rBmBEV-rAAVs based on time-consuming and labor-intensive plaque screening is avoided, and convenient, low-cost, efficient and large-scale preparation of rBmBEV-rAAVs of lower generations is achieved, laying a foundation for the establishment and application of a silkworm larvae / pupae-rAAV preparation production platform with Chinese characteristics.

[0040] (3) Compared with traditional BMN cells that can only be cultured adherently, the low-serum suspension culture BMN cells provided by the present invention that can be cultured adherently in Grace-supplemented insect medium containing 10% fetal bovine serum by volume make it easier to rescue P1 generation budding recombinant silkworm nuclear polyhedrosis virus (rBmNPV (Budded virus, rBmBEV), amplify rBmBEV seeds, and produce recombinant adeno-associated virus or express exogenous proteins based on the silkworm baculovirus expression system. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1 Schematic diagram of the preparation of rAAV based on the shuttle vector Bombyx mori baculovirus (rBmNPV);

[0042] Figure 2It is the BMN cell suspension acclimation and the rescue of rBmBEV-rAAV progeny;

[0043] Figure 3 It is to infect BMN cells with a single rBmNPV to produce rAAV and analyze the titer, empty shell rate, and infection activity of the prepared AAV vector;

[0044] Figure 4 The expression of AAV Rep protein and capsid protein VP1 / VP2 / VP3 in traditional adherent, suspension, and adherent-to-suspension BMN cells at different MOI values;

[0045] Figure 5 The purpose is to compare the rAAV yield and infection activity of adherent, suspended, and traditional adherent BMN cells. DETAILED DESCRIPTION

[0046] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0047] The content of fetal bovine serum and the content of HyPep1510 in the embodiments of the present invention both refer to the volume percentage.

[0048] Example 1: Recombinant adeno-associated virus (rAAV) preparation system and preparation method

[0049] The recombinant adeno-associated virus preparation system provided in this embodiment includes: a) low-serum suspension cultured BMN cells and / or adherent cultured cells of low-serum suspension cultured BMN cells, b) a single recombinant Bombyx mori nuclear polyhedrosis virus, a single recombinant Bombyx mori nuclear polyhedrosis virus infects a host cell or the host can at least produce the functional protein required for the packaging of the recombinant adeno-associated virus. Among them, the low-serum suspension cultured BMN cells are BMN cells suspended and cultured in a culture medium containing 2% fetal bovine serum. The adherent cultured cells of the low-serum suspension cultured BMN cells are low-serum suspension cultured BMN cells adherently grown in Grace supplemented insect culture medium containing 10% fetal bovine serum.

[0050] The recombinant adeno-associated virus preparation method provided in this embodiment adopts the above-mentioned recombinant adeno-associated virus preparation system to prepare the recombinant adeno-associated virus, and the preparation method comprises the following steps: infecting low-serum suspension cultured BMN cells with a single recombinant silkworm nuclear polyhedrosis virus, or infecting adherent cultured cells of low-serum suspension cultured BMN cells with a single recombinant silkworm nuclear polyhedrosis virus, and after the infection, collecting the culture supernatant liquid and cell precipitate respectively, lysing the cell precipitate and separating and purifying to obtain the recombinant adeno-associated virus.

[0051] The recombinant adeno-associated virus preparation system and preparation method are described in detail below.

[0052] 1. Recombinant adeno-associated virus preparation system

[0053] (1) Preparation of BMN cells in low-serum suspension culture

[0054] BMN cells (CRL-8910) were purchased from ATCC. BMN cells were first acclimated to adherent growth in Grace supplemented insect medium (Thermo Fisher Scientific, 11605102) supplemented with 10% fetal bovine serum (FBS, Gibco, 12657-029). After the cells stabilized, they were then acclimated to adherent growth in a medium containing 7.5% and 5% FBS in a stepwise manner. In a mixed medium consisting of Sf9 insect cell serum-free medium (Shanghai Yuanpei Biotechnology Co., Ltd., H832KJ) and Grace supplemented insect medium containing 0.5% HyPep1510 (see Mi Sun et al., 2005, Biotechnol Appl Biochem, vol.42, Pt 1). Afterwards, suspension acclimation (27.5°C / 115rpm, Shanghai Zhicheng Analytical Instrument Manufacturing Co., Ltd., ZWY-2102C) was started in a shake flask (125mL shake flask, Wuxi Nice Life Science Co., Ltd., 781111). BMN cells were suspended and acclimated to a concentration of 3% and 2% FBS, which was gradually reduced. The BMN cells were cultured in a mixed medium consisting of Sf9 insect cell serum-free medium and Grace supplemented insect medium containing 0.5% HyPep1510. Finally, the BMN cells were stabilized in a mixed medium supplemented with 0.5% HyPep1510 and 2% FBS, i.e., low-serum suspension cultured BMN cells. Figure 2 As shown in a.

[0055] In order to clarify the division and growth of the low-serum suspension cultured BMN cells obtained above, the acclimated BMN cells were cultured at 5×10 5 The cells were inoculated at a density of 10 cells / mL in a shake flask for suspension culture and the cells were counted for 10 consecutive days. Figure 2 The results showed that the growth rate of BMN cells in suspension culture was the highest on the 4th day of culture, and the cell density was the highest on the 7th day of culture, close to 3×10 6 cells / mL, with a doubling time of approximately 48 hours.

[0056] (2) Preparation of adherent culture cells of low-serum suspension cultured BMN cells

[0057] Insect cells based on adherent culture are an effective method for rescuing recombinant baculoviruses. Whether the acclimated low-serum suspension cultured BMN cells can be switched to adherent culture still needs further verification. Therefore, low-serum suspension cultured BMN cells and traditional adherent cultured BMN cells were added to Grace-supplemented insect medium containing 10% fetal bovine serum at a concentration of 1×10 5 Cells / mL were inoculated in 6-well culture plates, and the cells were counted for 7 consecutive days to compare the differences between the two. Figure 2 c. The results showed that the doubling time of the two different types of adherent cultured BMN cells was similar, about 36 hours; the growth of the suspension-transferred adherent cultured BMN cells and the traditional adherent cultured BMN cells was similar in the first two days of culture; the proliferation rate of the traditional adherent cultured BMN cells was the fastest on the third day of culture, and the cell density was slightly higher than that of the suspension-transferred adherent cultured BMN cells; on the fourth day of culture, although the proliferation rate of the suspension-transferred adherent cultured BMN cells was the fastest, its cell density was still lower than that of the traditional adherent cultured BMN cells; and on the fifth, sixth, and seventh days of culture, the proliferation rates of the two different types of adherent cultured BMN cells slowed down. This indicates that low-serum suspension-cultured BMN cells can adhere to the wall in Grace supplemented insect medium containing 10% fetal bovine serum, and the cell growth characteristics are similar to those of traditional adherent cultured BMN cells. The suspension-transferred adherent cultured BMN cells in the logarithmic growth phase, 75% to 85% fusion and uniform distribution, and in good condition are the adherent cultured cells of low-serum suspension-cultured BMN cells.

[0058] (3) Preparation of a single recombinant silkworm nuclear polyhedrosis virus

[0059] 1) Preparation of a single BmNPV-rAAV recombinant bacmid

[0060] In order to determine the efficiency of rBmBEV rescue by BMN cells transferred from suspension to adherent culture, the recombinant bacmid Bm3.3-rAAV2-CMV-eGFP-hGH in Example 3 of the invention patent "A recombinant bacmid preparation system and BmNPV-rAAV recombinant bacmid, application number: CN202311779100.4" was amplified, and Bm3.3-rAAV9-CMV-eGFP-hGH was constructed with reference.

[0061] 2) Rescue of P1 generation rBmBEV-rAAV

[0062] The low-serum suspension culture BMN cells and the traditional adherent culture BMN cells were cultured at 1×10 6Cells / well were inoculated in 6-well plates for adherent culture. When the cell confluence reached 75% to 85%, 2 μg of recombinant bacmid Bm3.3-rAAV2-CMV-eGFP-hGH and Bm3.3-rAAV9-CMV-eGFP-hGH were transfected into the cells according to the instructions of the Mirus transfection kit (TransIT-Insect Transfection Reagent, MRI6100). The medium was not changed in the middle. Three days after transfection, the supernatant was collected by centrifugation at 2500 rpm for 10 min. An appropriate amount of supernatant was taken and treated at room temperature for 15 min according to the method described in "Alkaline polyethylene glycol-based method for direct PCR from bacteria, eukaryotic tissue samples, and whole blood" (Homczynski P et al., Biotechniques. 2006 Apr; 40(4): 454, 456, 458.), and the BEV titer was determined by qPCR. The P1 generation rBmBEV-rAAV rescued by transfection with Bm3.3-rAAV2-CMV-eGFP-hGH was recorded as BEV / Bm3.3-rAAV2, and the P1 generation rBmBEV-rAAV rescued by transfection with Bm3.3-rAAV9-CMV-eGFP-hGH was recorded as BEV / Bm3.3-rAAV9.

[0063] The results showed that whether the BMN cells were cultured in suspension or adherent culture, they were all illuminated by green fluorescent protein after being transfected with the recombinant bacmid. Figure 2 As shown in d; the abundance of fluorescent protein expression in BMN cells transfected with Bm3.3-rAAV9-CMV-eGFP-hGH was stronger than that in Bm3.3-rAAV2-CMV-eGFP-hGH, and the fluorescence brightness of BMN cells transferred from suspension to adherent culture was slightly higher than that of traditional adherent culture; the rBmBEV titer in the supernatant of BMN cells transferred from suspension to adherent culture was significantly higher than that of rBmBEV titer rescued by BMN cells using traditional adherent culture (see Figure 5). Figure 2 e). This indicates that suspension-adherent BMN cells can be used to efficiently rescue rBmBEVs.

[0064] 3) Amplification of rBmBEV

[0065] Step 3) is an optional step. The prepared P1 generation rBmBEV-rAAV is used to infect BMN cells cultured in low serum suspension, or the adherent cultured cells infected with BMN cells cultured in low serum suspension are further amplified to obtain progeny rBmBEV-rAAV.

[0066] 2. Preparation method of recombinant adeno-associated virus

[0067] The P1 generation rBmBEV-rAAV or the progeny rBmBEV-rAAV was used to infect low-serum suspension cultured BMN cells or adherent cultured cells of low-serum suspension cultured BMN cells. After 72 hours, the culture supernatant (the cell supernatant is the progeny rBmBEV-rAAV, which can be used to further infect host cells or prepare rAAV in the host) and the cell precipitate were collected respectively. The cell precipitate was lysed and separated and purified to obtain the recombinant adeno-associated virus (rAAV).

[0068] To verify whether the adapted low-serum suspension cultured BMN cells can be used to produce rAAV, 1×10 6 The conventional adherent BMN cells were seeded at 1×10 cells / well and 1×10 6 4 mL of BMN suspension cells were cultured with 10 cells / mL, and then the BMN cells cultured in different ways were infected with P1 BEV / Bm3.3-AAV2 at MOI=10 for comparison. The results showed that both types of BMN cells were illuminated by green fluorescent protein 3 days after infection (see Appendix Figure 3 a), and the titer of P2 generation BEV / Bm3.3-AAV2 in the supernatant of suspension cultured BMN cells was higher than that of traditional adherent cultured BMN cells (Appendix Figure 3 b). Western Blot was used to quantitatively analyze the expression of AAV Rep protein and capsid protein VP1 / 2 / 3 in cell pellets (uninfected conventional adherent BMN cells in one well, conventional adherent BMN cells in one well infected with rBmBEV, and 1 mL of suspended BMN cells infected with rBmBEV, centrifuged at 2500 rpm). GAPDH was used as an internal reference protein. Figure 3 As shown in Figure c, all functional proteins required for AAV production were detected in BMN cells infected with BEV / Bm3.3-AAV2, among which the expression of Rep52 was higher than that of Rep78, and the expression abundance of capsid protein VP2 was lower; compared with traditional adherent BMN cells, the expression abundance of Rep52 in suspension cultured BMN cells was higher, the expression abundance of Rep78 was lower, and the ratio of VP1, VP2, and VP3 was closer to 1:1:10. Therefore, using rBmBEV to infect low-serum suspension cultured BMN cells is more conducive to the production of rAAV.

[0069] Furthermore, 2 × 10 650mL of BMN suspension cells were inoculated at a density of 10 cells / mL, and P1 generation BEV / Bm3.3-AAV2 was added to the shake flask at an MOI of 10 for infection for 3 days. The BMN cell pellets were collected and purified by iodixanol density gradient centrifugation to obtain rAAV2-CMV-eGFP-hGH. The same method as above (P1 generation BEV / Bm3.3-AAV9 infected BMN suspension cells) was used to produce rAAV9-CMV-eGFP-hGH. AAV9 produced by 293T cells was used as a positive control, and the AAV derived from the above BMN suspension cells was quantitatively detected by silver staining and qPCR. The results showed that whether it was AAV2 or AAV9 produced by BMN suspension cells, their capsid proteins VP1, VP2, and VP3 could be detected and the ratio was close to 1:1:10 (see Appendix). Figure 3 d, e), the silver staining results were consistent with the AAV titer determined by qPCR (Appendix Figure 3 f). In addition, transmission electron microscopy (TEM, Public Analysis and Testing Center, Southern University of Science and Technology) was used to image the AAV prepared based on BMN suspension cells, and it was observed that AAV2 (attached Figure 3 g) and AAV9 (attached Figure 3 The virus particles are all spherical in shape with a size of 20-25 nm.

[0070] In order to test the infection activity of AAV derived from BMN suspension cells, the in vitro and in vivo experiments conducted in this example include: 1) taking 3 μL of AAV and adding it to a 96-well plate with 293T cells; 2) using a brain stereotaxic injection system to inject 300 nL of AAV into the vlPAG brain region of mice (see attached) Figure 3 k). The results showed that after 48 hours of infection, 293T cells were illuminated by green fluorescent protein (see Appendix Figure 3 i, j); Although the fluorescence expression abundance of 293T cells infected with AAV2(BMN) was much higher than that of 293T cells infected with AAV9(BMN), the infection efficiency of these two AAVs(BMN) on the vlPAG brain cells of mice was similar (Appendix Figure 3 k, l), the difference is that the inflammation caused by injection of AAV9 (BMN) in the vlPAG region is more obvious. This shows that rAAV with high titer and infectious activity can be prepared by infecting BMN cells in suspension culture with rBmBEV. In summary, the present invention successfully established a BMN cell / rBmNPV-AAV preparation system and preparation method, Figure 1 Schematic diagram of the preparation of rAAV based on the shuttle vector Bombyx mori baculovirus (rBmNPV).

[0071] Example 2: MOI value of rAAV prepared by infecting BMN cells with rBmNPV

[0072] The multiplicity of infection (MOI) of rBmNPV is a key parameter that determines the AAV production and the yield of progeny rBmBEV. Therefore, it is necessary to clarify the optimal MOI value of the BMN cell / rBmNPV-AAV preparation system in Example 1 of the present invention.

[0073] In a 6-well culture plate, 1 × 10 6 The cells / well were inoculated with traditional adherent BMN cells and suspension BMN cells and cultured until 80% confluence (about 1.5×10 6 / well), in a 50 mL centrifuge tube at 1 × 10 6 4 mL of BMN suspension cells were cultured with 10 cells / mL, and the titers of P1 generation BEV / Bm3.3-AAV2 and BEV / Bm3.3-AAV9 were further determined by qPCR, and the BMN cells cultured in the above three ways were infected at MOI=0, 0.5, 1, 3, 5, and 10, respectively. After 3 days, the cell pellets were collected (1 mL of the suspension cultured BMN cells were collected for cell pellets), and the expression of AAV Rep protein and capsid protein VP1 / 2 / 3 in BMN cells at different gradient MOI values ​​was detected by Western Blot. As shown in the attached figure, Figure 4 As shown, BMN cells were infected with BEV / Bm3.3-AAV2. When MOI=10, the expression abundance of AAV Rep protein and capsid protein VP1 / 2 / 3 in BMN cells cultured in traditional adherent and suspension cultures was the highest, while the expression abundance of AAV Rep protein and capsid protein VP1 / 2 / 3 in BMN cells cultured in suspension-adherent cultures was close at different MOI values ​​of 3 to 10 (see Figure 2). Figure 4 a); When BEV / Bm3.3-AAV9 was used to infect BMN cells, the expression abundance of AAV Rep protein and capsid protein VP1 / 2 / 3 was close between the MOI values ​​of 3 and 10 in suspension and suspension-adherent BMN cells, while the expression abundance of AAV Rep protein and capsid protein VP1 / 2 / 3 in traditional adherent BMN cells at MOI=5 was close to that at MOI=10 (see Appendix Figure 4b). Regardless of whether BEV / Bm3.3-AAV2 or BEV / Bm3.3-AAV9 is used to infect BMN cells, compared with adherent cultured BMN cells, suspension cultured BMN cells can detect the functional proteins required for AAV production at different MOI gradients, and the expression abundance of AAV Rep protein and capsid protein VP1 / 2 / 3 is not much different between different MOI values, which indicates that suspension cultured BMN cells are more beneficial to AAV production. Considering the dosage of BEV / Bm3.3-AAV and the expression abundance of AAV Rep protein and capsid protein VP1 / 2 / 3 in the corresponding BMN cells, this example shows that the optimal MOI value for preparing rAAV by infecting BMN cells with rBmNPV is 3 to 5.

[0074] Furthermore, the yields of AAV2 and AAV9 in suspension-adherent cells (sa), suspension cells (s), and traditional adherent cells (a) were analyzed with MOI = 3. 6 cells / mL, 50mL), a BMN cells (1×10 8 The BMN cells were infected with BEV / Bm3.3-AAV2 and BEV / Bm3.3-AAV9 at MOI=3. After 3 days, the above BMN cells were all marked with eGFP, among which the expression of fluorescent protein in sa cells was the highest (see Appendix). Figure 5 a). Collect cell pellets and purify rAAV2-CMV-eGFP-hGH (AAV2) and rAAV9-CMV-eGFP-hGH (AAV9) by iodixanol density gradient centrifugation, and perform silver staining and qPCR detection (AAV9 produced by 293T cells was used as a positive control), as shown in the attached Figure 5 As shown in Figures 5b and 5c, BMN cells cultured in different ways can be used to produce AAV2 and AAAV9. The titer of AAV9 is generally higher than that of AAV2, and BMN cells cultured in suspension are more conducive to producing high-titer AAV. The results of 293T cell infection showed that the eGFP expression intensity of 293T cells infected with AAV2 was generally higher than that infected with AAV9, among which the eGFP expression abundance was highest after 293T cells were infected with AAV2(s); compared with traditional adherent cultured BMN cells, AAV produced by domesticated suspension BMN cells, whether cultured in adherent (sa) or suspension (s), had better infection activity on 293T cells (attached). Figure 5 d, 5e).

[0075] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.

Claims

1. A method for preparing a single recombinant silkworm nuclear polyhedrosis virus, characterized in that: The preparation method is selected from one of methods 1-3: Method 1: A single BmNPV-rAAV recombinant bacmid was transfected into adherent cultured BMN cells cultured in low serum suspension culture to rescue the first generation budding recombinant Bombyx mori nuclear polyhedrosis virus, which was recorded as P1 generation rBmBEV-rAAV, i.e., a single recombinant Bombyx mori nuclear polyhedrosis virus; Method 2: Transfect the adherent cultured cells of low-serum suspension cultured BMN cells with a single BmNPV-rAAV recombinant bacmid to rescue the P1 generation rBmBEV-rAAV; Infect the adherent cultured cells of low-serum suspension cultured BMN cells with the P1 generation rBmBEV-rAAV to obtain the progeny rBmBEV-rAAV, which is a single recombinant Bombyx mori nuclear polyhedrosis virus; Method 3: Transfect the adherent cultured cells of low-serum suspension cultured BMN cells with a single BmNPV-rAAV recombinant bacmid to rescue the P1 generation rBmBEV-rAAV; Infect the low-serum suspension cultured BMN cells with the P1 generation rBmBEV-rAAV to obtain the progeny rBmBEV-rAAV, which is a single recombinant Bombyx mori nuclear polyhedrosis virus; The single BmNPV-rAAV recombinant bacmid comprises a recombinant adeno-associated virus core expression element ITR-GOI, a Rep gene expression cassette and a Cap gene expression cassette.

2. The preparation method according to claim 1, characterized in that: The low-serum suspension cultured BMN cells are BMN cells suspended and cultured in a culture medium containing 2% fetal bovine serum by volume; And / or, the adherent cultured cells of the low-serum suspension cultured BMN cells are low-serum suspension cultured BMN cells adherently grown in Grace supplemented insect medium containing 10% by volume fetal bovine serum.

3. The preparation method according to claim 2, characterized in that: The preparation of low-serum suspension cultured BMN cells comprises: firstly, the BMN cells are domesticated to grow adherently in a Grace supplemented insect medium containing 10% by volume of fetal bovine serum, then the BMN cells are adherently domesticated to a mixed medium consisting of an insect cell serum-free medium with a gradually decreasing fetal bovine serum content and a Grace supplemented insect medium, then the BMN cells are suspended and domesticated to a mixed medium consisting of an insect cell serum-free medium with a gradually decreasing fetal bovine serum content and a Grace supplemented insect medium, and finally the BMN cells are stabilized in a mixed medium consisting of an insect cell serum-free medium with a 2% by volume content of fetal bovine serum and a Grace supplemented insect medium, and the obtained cells are low-serum suspension cultured BMN cells; Preferably, HyPep 1510 is additionally added to the mixed medium consisting of the insect cell serum-free medium and Grace supplemented insect medium; Preferably, the volume percentage of HyPep 1510 is 0.5%; Preferably, the threshold value of the volume percentage of fetal bovine serum for BMN cell adherence and suspension acclimation is 5%, that is, when the volume percentage of fetal bovine serum in the mixed culture medium is lower than 5%, the BMN cells cultured adherently are switched to suspension culture; Preferably, the volume percentage of the fetal bovine serum decreases step by step in a gradient of 10%, 7.5%, 5%, 3%, and 2%.

4. The preparation method according to claim 2, characterized in that: The preparation of the adherent cultured cells of the low-serum suspension cultured BMN cells comprises: adding the low-serum suspension cultured BMN cells to Grace supplemented insect culture medium containing 10% by volume of fetal bovine serum for adherent culture, and preparing BMN adherent cells that are in logarithmic growth phase, 75% to 85% fused and evenly distributed, and in good condition, namely, the adherent cultured cells of the low-serum suspension cultured BMN cells.

5. The preparation method according to claim 1, characterized in that: The promoter driving the expression of the recombinant adeno-associated virus Cap gene and Rep gene is derived from AcMNPV; Preferably, the promoter driving the expression of the Cap gene is Pp10; Preferably, the promoter driving the expression of the Rep gene is Pph; Preferably, the recombinant adeno-associated virus core expression element ITR-GOI and the Cap gene expression frame are located at least in the same non-essential locus of the Bombyx mori nuclear polyhedrosis virus genome.

6. A single recombinant Bombyx mori nuclear polyhedrosis virus prepared by the preparation method according to any one of claims 1 to 5.

7. A recombinant adeno-associated virus preparation system, characterized in that: The recombinant adeno-associated virus preparation system comprises: a) the low-serum suspension cultured BMN cells according to claim 1 and / or the adherent cultured cells of the low-serum suspension cultured BMN cells according to claim 1, and b) a recombinant Bombyx mori nuclear polyhedrosis virus, wherein the recombinant Bombyx mori nuclear polyhedrosis virus infects a host cell or the host can at least produce the functional protein required for the packaging of the recombinant adeno-associated virus.

8. The recombinant adeno-associated virus preparation system according to claim 7, characterized in that: The recombinant Bombyx mori nuclear polyhedrosis virus is the single recombinant Bombyx mori nuclear polyhedrosis virus according to claim 6.

9. A method for preparing a recombinant adeno-associated virus, characterized in that: The recombinant adeno-associated virus is prepared using the preparation system described in claim 7, and the preparation method comprises the following steps: infecting the low-serum suspension cultured BMN cells described in claim 1 with the recombinant silkworm nuclear polyhedrosis virus, or infecting the adherent cultured cells of the low-serum suspension cultured BMN cells described in claim 1 with the recombinant silkworm nuclear polyhedrosis virus, and after the infection, collecting the culture supernatant liquid and cell precipitate respectively, lysing the cell precipitate and separating and purifying to obtain the recombinant adeno-associated virus.

10. The method for preparing a recombinant adeno-associated virus according to claim 9, characterized in that: The cell precipitate was purified by iodixanol density gradient centrifugation; Preferably, the MOI of the recombinant Bombyx mori nuclear polyhedrosis virus is 3 to 5; Preferably, the infection time is 72 hours.